生物股份(600201.SH):經營範圍新增獸用生物藥品、化學藥品製劑製造和銷售等
格隆匯 8 月 14日丨生物股份(600201.SH)公佈,為優化公司經營業務結構,更好地促進公司動保產業的持續發展,於2020年8月13日召開第十屆董事會第六次會議,會議審議通過了《關於變更公司經營範圍的議案》。
修訂前:生物技術推廣應用;對生物藥品投資管理、醫療器械製造投資管理;健康醫療產業投資管理;高新技術開發應用;房地產開發;物業管理。(依法須經批准的項目,經相關部門批准後方可開展經營活動)
修訂後:獸用生物藥品製造和銷售;獸用化學藥品製劑製造和銷售;化學試劑和助劑製造和銷售;生物藥品製劑製造和銷售;生物技術開發、轉讓、諮詢服務;先進醫療設備及器械製造和銷售;貨物進出口、技術進出口;物業管理。(依法須經批准的項目,經相關部門批准後方可開展經營活動)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.